Skip to main content

Table 2 Demographic data

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Parameter

Febuxostat 40 mg OD (A)

TB 500 mg BID (B)

TB 1000 mg BID (C)

No. of subjects

19

18

18

Gender (M/F)

14 M / 5F

13 M / 5F

14 M / 4F

Age (Years)

50.95 ± 9.82

53.17 ± 8.91

50.78 ± 8.79

BMI (Kg/m2)

26.78 ± 1.29

25.52 ± 0.87

25.63 ± 1.61

  1. OD once daily, BID twice daily
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us